Tirzepatide Linked to Reduced Cardiovascular Risk Post-Intervention
Tirzepatide is associated with reduced cardiovascular risks and improved outcomes in patients undergoing PCI and TAVR, according to new research.
Ayla Demirhan ·
New research indicates that tirzepatide, a GLP-1 receptor agonist, is associated with reduced cardiovascular risks in patients undergoing specific cardiac procedures. One study observed a 62% lower mortality risk among participants receiving tirzepatide after percutaneous coronary intervention (PCI).
Another study found that patients with obesity undergoing transcatheter aortic valve replacement (TAVR) who received tirzepatide experienced improved outcomes and lower event-free survival compared to those not on the medication. These findings suggest potential benefits for high-risk cardiovascular patient populations.
The research, presented at a scientific session, has not yet undergone peer review. While previous studies have established broader cardiometabolic benefits of tirzepatide, its impact on patients undergoing interventional heart procedures had not been extensively evaluated.
Further prospective studies are needed to validate these observations.